Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Two Kennedy Institute scientists have proposed a solution to a puzzle of the human immune system: how our immune system scales its response in proportion to any threat to our health to make it 'just right'. Their ideas, published in the journal Trends in Immunology, could support a range of medical research.

© Shutterstock/ Juan Gaertner

Studies by various research groups around the world have shown how the T-cells, which are a vital part of our immune system, only perceive the world in a black and white fashion at any moment in time. This means that a minor threat could trigger a response large enough to injure healthy tissue if the T cells acted impulsively on these momentary signals. However, studies also show that the body can match the level of T-cell response to the seriousness of an infection in most situations.

Many biological processes hit an upper limit, known as saturation. But with T-cell response this effect is suppressed, allowing the response to be just right even if the threat varies over a range of 10,000-fold. Overcoming saturation allows the immune system to keep scaling up its response to meet the demands of severe infection. - Dr Viveka Maya

Michael Dustin, Professor of Immunology at the Kennedy Institute explained: 'While an overwhelming T-cell response might on the face of it sound effective, it brings risks of immunopathology, where an over-active immune system destroys healthy human tissue, not just the invading disease-causing pathogen.

'Scaling the immune response is therefore a safer option, and we know that is what happens. Until now, however, no one had suggested how the body does that.'

Dr Viveka Mayya, a scientist working with Prof. Dustin, considered the duration of the interactions between T-cells and the dendritic cells that activate T-cell responses as a possible solution to this mystery. Studies from several labs, including Prof. Dustin's, found that as the severity of an infection increased so did the length of these interactions. T-cells are usually 'motile' – they move around the body – but when an infection is happening, they slow down and accumulate around the dendritic cells that help the T cells read the severity of the infection. Longer interactions therefore lead to greater accumulation of T cells over time – a bigger immune response.

This is because the dendritic cells affect proteins called transcription factors in T cells in a time dependent manner. Some of these transcription factors act to reduce the levels of components needed for T-cell movement, causing movement to be slowed and prolonging the interaction with dendritic cells.

At the same time, other transcription factors are either increased or decreased in a way that prevents the process from 'saturating'. This allows transcription factors that control the growth and metabolism of T cells to accumulate in proportion to the initial microbial threat, allowing a build-up of T cells to the right level.

Dr Viveka Mayya said: 'Many biological processes hit an upper limit, known as saturation. But with T-cell response this effect is suppressed, allowing the response to be just right even if the threat varies over a range of 10,000-fold. Overcoming saturation allows the immune system to keep scaling up its response to meet the demands of severe infection.'

By understanding more about how the immune system works, the pair hope to advance other areas of research.

Prof. Dustin said: 'This knowledge could be applied in vaccine development, where you are looking to cause a strong immune reaction but with minimum risk. It also offers more information for the study of auto-immune diseases: by understanding how the immune system usually gets the response 'just right', we are better placed to see how responses go wrong in autoimmunity and chronic infection and therefore how we can prevent or correct such errors.'

The paper, What Scales the T Cell Response?, is published by Trends in Immunology (doi:10.1016/j.it.2016.06.005).

Similar stories

Professor Dani Prieto-Alhambra elected to ISPE Board of Directors

Dani Prieto-Alhambra, Professor of Pharmaco- and Device Epidemiology at NDORMS, has been elected as the Academic representative for Europe and Africa on the International Society of Pharmaco-Epidemiology Board of Directors.

New research from the Kennedy Institute of Rheumatology identifies a role for CD200 in limiting atherosclerosis

A new study published in Circulation Research shows that CD200, an inhibitory immune checkpoint, reduces the development of atherosclerosis.

EPSRC funds research to avert an antibiotics apocalypse

Researchers at the Kennedy Institute join a collaboration to find new ‘drug-free’ ways of treating illnesses where current treatments have become ineffective due to antibiotic resistance.

Research finds that surgery for Dupuytren’s disease is effective, but repeat operations come with higher risks

Research by NDORMS Dominic Furniss, Professor of Plastic and Reconstructive Surgery, finds that surgery for the common hand disorder Dupuytren’s disease is safe and effective. However, repeat surgery could carry higher risks of complications such as finger amputation.

Celebrating World Clubfoot Day

More than 30,000 children in Africa are born with clubfoot each year. With treatment simply not available where they live, many thousands of these children get no treatment and end up with severe deformities that make it hard and very painful to walk.

Repurposed drug can induce remission of inflammatory arthritis

Researchers at the Kennedy Institute demonstrate that the drug decitabine can boost regulatory T cell responses.